Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly
Marques-Pamies, Montserrat (Hospital Municipal de Badalona)
Gil, Joan (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Valassi, Elena (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Hernández García, Marta (Hospital Universitari Arnau de Vilanova)
Biagetti, Betina (Hospital Universitari Vall d'Hebron)
Giménez-Palop, Olga (Parc Taulí Hospital Universitari. Institut d'Investigació i Innovació Parc Taulí (I3PT))
Martínez, Silvia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Carrato, Cristina (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Pons, Laura (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Villar-Taibo, Rocío (Hospital Clínico Universitario (Santiago de Compostela, Galícia))
Araujo-Castro, Marta (Hospital Universitario Ramón y Cajal (Madrid))
Blanco, Concepción (Hospital Universitario Príncipe de Asturias)
Simón, Inmaculada (Hospital Universitari Joan XXIII de Tarragona)
Simó-Servat, Andreu (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya))
Xifra, Gemma (Hospital Universitari de Girona Doctor Josep Trueta)
Vázquez, Federico (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Pavón, Isabel (Hospital Universitario de Getafe)
García-Centeno, Rogelio (Hospital General Universitario Gregorio Marañón)
Zavala, Roxana (Hospital Universitari Joan XXIII de Tarragona)
Hanzu, Felicia A (Hospital Clínic i Provincial de Barcelona)
Mora, Mireia (Hospital Clínic i Provincial de Barcelona)
Aulinas, Anna (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya))
Vilarrasa, Nuria (Instituto de Salud Carlos III)
Librizzi, Soledad (Hospital Universitario 12 de Octubre)
Calatayud, María (Hospital Universitario 12 de Octubre)
de Miguel, Paz (Hospital Clínico San Carlos (Madrid))
Alvarez-Escola, Cristina (Hospital Universitario La Paz (Madrid))
Picó Alfonso, Antonio M (Instituto de Investigación Sanitaria y Biomédica de Alicante)
Sampedro, Miguel (Hospital Universitario de La Princesa)
Salinas, Isabel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Fajardo-Montañana, Carmen (Hospital Universitari de la Ribera)
Cámara, Rosa (Hospital Universitari i Politècnic La Fe (València))
Bernabeu Morón, Ignacio (Hospital Clínico Universitario (Santiago de Compostela, Galícia))
Jordà, Mireia (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Webb, S. M 1952- (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya))
Marazuela, Mónica (Hospital Universitario de la Princesa (Madrid))
Puig Domingo, Manuel (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol)
Universitat Autònoma de Barcelona

Date:	2023
Abstract:	We previously described that a short version of the acute octreotide test (sAOT) can predict the response to first-generation somatostatin receptor ligands (SRLs) in patients with acromegaly. We have prospectively reassessed the sAOT in patients from the ACROFAST study using current ultra-sensitive GH assays. We also studied the correlation of sAOT with tumor expression of E-cadherin and somatostatin receptor 2 (SSTR2). A total of 47 patients treated with SRLs for 6 months were evaluated with the sAOT at diagnosis and correlated with SRLs' response. Those patients whose IGF1 decreased to <3SDS from normal value were considered responders and those whose IGF1 was ≥3SDS, were considered non-responders. The 2 hours GH value (GH) after s. c. administration of 100 mcg of octreotide was used to define predictive cutoffs. E-cadherin and SSTR2 immunostaining in somatotropinoma tissue were investigated in 24/47 and 18/47 patients, respectively. In all, 30 patients were responders and 17 were non-responders. GH was 0. 68 (0. 25-1. 98) ng/mL in responders vs 2. 35 (1. 59-9. 37) ng/mL in non-responders (p<0. 001). GH = 1. 4ng/mL showed the highest ability to identify responders (accuracy of 81%, sensitivity of 73. 3%, and specificity of 94. 1%). GH = 4. 3ng/mL was the best cutoff for non-response prediction (accuracy of 74%, sensitivity of 35. 3%, and specificity of 96. 7%). Patients with E-cadherin-positive tumors showed a lower GH than those with E-cadherin-negative tumors [0. 9 (0. 3-2. 1) vs 3. 3 (1. 5-12. 1) ng/mL; p<0. 01], and patients with positive E-cadherin presented a higher score of SSTR2 (7. 5 ± 4. 2 vs 3. 3 ± 2. 1; p=0. 01). The sAOT is a good predictor tool for assessing response to SRLs and correlates with tumor E-cadherin and SSTR2 expression. Thus, it can be useful in clinical practice for therapeutic decision-making in patients with acromegaly.
Grants:	Ministerio de Economía y Competitividad PMP15/00027 Instituto de Salud Carlos III PMP22/00021
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Acromegaly ; Acute octreotide test ; Individualized treatment ; Precision medicine ; Prediction ; Somatostatin analogs
Published in:	Frontiers in endocrinology, Vol. 14 (october 2023) , ISSN 1664-2392

DOI: 10.3389/fendo.2023.1269787
PMID: 38027102

11 p, 1.4 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Parc Taulí Research and Innovation Institute (I3PT
Articles > Research articles
Articles > Published articles